Research-grade Tirzepatide. First-in-class dual GIP/GLP-1 receptor agonist studied for synergistic effects on metabolic and energy pathways.
Tirzepatide is a first-in-class dual incretin research compound — a single molecule that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. This dual agonism produces synergistic effects not seen with single-receptor research compounds.
Tirzepatide engages both GIP and GLP-1 receptors with high affinity. Research has shown the GIP receptor activity may complement GLP-1 effects on insulin secretion while the GLP-1 component contributes to satiety signaling and gastric emptying delay. The dual mechanism is studied for its synergistic outcomes versus single-pathway compounds.
Tirzepatide is investigated in research models for: dual incretin signaling, glucose-insulin dynamics, lipid metabolism, satiety pathway integration, comparative studies vs single-agonist GLP-1 compounds, and metabolic syndrome research.
| Compound | Tirzepatide |
| Available Strengths | 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg, 80mg |
| Purity | ≥99% (verified by HPLC) |
| Form | Lyophilized powder |
| Storage | -20°C, protected from light |
| Reconstitution | Bacteriostatic water (sold separately) |
| Shelf Life | 36 months (lyophilized, properly stored) |
| Certificate of Analysis | Available upon request — contact us |
Add bacteriostatic water slowly. Use within 28 days.
Lyophilized: -20°C. Reconstituted: 2-8°C.
For research use only. Not for human consumption.